Seegene Inc., a South Korea-based company providing a total solution for PCR molecular diagnostics, declared the commencement of sharing its syndromic PCR technologies all over the world in an effort to prevent future pandemics.
Seegene aims to partner with nationally reputable companies in each country to develop and manufacture customized syndromic PCR tests locally through access to Seegene’s proprietary technologies. This effort will enable partnering companies to effectively address potential disease outbreaks.
Further reading: What Happens When We Forget the COVID-19 Pandemic?
Embracing an open innovation model, Seegene invites leading companies in each country to join this network and collectively develop hundreds or even thousands of syndromic PCR assays annually to serve both local and global markets. The creation of a sustainable global community will catalyze the development of novel and innovative applications for PCR technologies worldwide.
Seegene highlighted its automated testing system, ‘One System,’ which is aimed at decentralizing lab testing at an affordable price.
“The major challenge in PCR molecular diagnostics is the number of different laboratory instruments required to run assays from different manufacturers,” says Jong-Yoon Chun, PhD, CEO of Seegene. “We believe that consolidating all PCR tests onto One System will revolutionize assay developer and user experiences in syndromic PCR tests.”
On March 22, 2023, Seegene signed the first One System global partnership agreement with the leading diagnostic company in Israel, Hy Laboratories Ltd (Hylabs). Seegene is committed to sharing its syndromic PCR technologies with Hylabs to address local needs and is looking forward to having the Israeli scientific community participate in this global partnership.
“This agreement will leverage Hylab’s five decades of leadership in the molecular and microbiology diagnostics,” says Doron Cohen, president of Hylabs. “This endeavor maximizes both companies’ 15 years extensive collaboration as enablers of frontier medical technology in public health.”
The signing of this agreement marks the beginning of Seegene’s proactive search for additional partners to join this global network that will leverage Seegene syndromic PCR technologies, including One System, to advance the quality of life and welfare of people around the world, the company says.